Best Peptides for Metabolic and Weight Loss Research
Research category
Best peptides for metabolic research.
Metabolic research has been transformed by the incretin-mimetic class over the past five years. Retatrutide is the new benchmark for total weight-loss magnitude; Tesamorelin remains the standard for visceral-fat-specific reduction; MOTS-c offers a mitochondrial-derived alternative mechanism; the CJC-1295 plus Ipamorelin blend covers the GH axis. Here is the working order.
Quick answer
Retatrutide for total fat mass and weight-loss magnitude. Tesamorelin for visceral-fat-specific reduction. MOTS-c for mitochondrial/AMPK-axis research. CJC-1295 + Ipamorelin for GH-axis effects on body composition.
The shortlist for metabolic research
|
1
|
Highest magnitude Retatrutide Triple GLP-1/GIP/glucagon agonist. Phase 2 obesity data showed 24.2% mean body-weight reduction at 48 weeks (highest magnitude published for any pharmacological agent in this class). Active Phase 3 trials in obesity, type-2 diabetes, MASH, and obstructive sleep apnea. Currently the benchmark compound for metabolic peptide research. |
|
2
|
Visceral fat specific Tesamorelin FDA-approved GHRH analogue (2010, HIV lipodystrophy). Produces visceral-adipose-tissue-specific reduction through pulsatile endogenous GH release. Most clinically validated GHRH analogue in the catalog. Active research in MASLD, body composition, and aging. |
|
3
|
AMPK axis MOTS-c Mitochondrial-derived peptide encoded in the 12S rRNA gene. Activates AMPK independently of cellular AMP:ATP ratio. Insulin sensitivity improvements, resistance to diet-induced obesity, and exercise-induced metabolic regulation in published research. Unique mitochondrial-encoded mechanism. |
|
4
|
GH axis CJC-1295 + Ipamorelin GHRH plus selective GHRP combined preparation. Produces synergistic endogenous GH pulse 2-3x larger than either alone, without cortisol or prolactin elevation. Standard research stack for GH-axis effects on lean mass, fat oxidation, and recovery. Read the CJC-1295 + Ipamorelin guide →Order from the library → |
How to choose between them
If your research question is about maximum total body-weight reduction, Retatrutide is the current benchmark. Phase 2 data exceeds every previous reference compound, and Phase 3 results will determine its regulatory trajectory.
If your research specifically targets visceral adipose tissue (and is willing to accept lower total-fat-mass changes), Tesamorelin’s visceral-specific reduction profile is the most-established option.
If your research is on the underlying cellular metabolic machinery (AMPK signaling, mitochondrial biogenesis, insulin sensitivity at the cellular level), MOTS-c provides a mechanism distinct from the incretin and GHRH pathways.
For research on body composition through the GH axis (lean mass effects, fat oxidation, recovery), the CJC-1295 + Ipamorelin combination is the standard approach.
Stack design for this category
Combined research using Retatrutide plus Tesamorelin is increasingly studied because the two mechanisms target different fat compartments — total fat mass (Retatrutide) and visceral fat (Tesamorelin) — without overlap or interference.
Adding MOTS-c to a metabolic stack provides a parallel cellular-energy-sensing arm that complements the receptor-mediated effects of Retatrutide and the GH-axis effects of Tesamorelin.
CJC-1295 + Ipamorelin is sometimes added to Retatrutide-based stacks when GH-axis effects on body composition are also relevant to the research question. The mechanisms do not interfere.
Compliance reminder
All compounds listed are sold by Aeternum Labs for in vitro laboratory research purposes only. They are not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease or condition.
Frequently asked questions
Is Retatrutide the most effective weight-loss peptide?
Based on published Phase 2 data, yes. Retatrutide’s 24.2% mean weight reduction at 48 weeks exceeds the highest approved semaglutide dose’s 14.9% over 68 weeks, and exceeds Phase 2/3 tirzepatide data. Direct head-to-head trials are not yet publicly reported but cross-trial comparisons consistently favor Retatrutide.
Does Tesamorelin work for general weight loss or just visceral fat?
Tesamorelin’s published effects are specifically on visceral adipose tissue rather than total body fat. For research focused on general weight loss endpoints, the incretin-mimetic class (Retatrutide, semaglutide, tirzepatide) produces larger effects. For visceral-fat-specific research, Tesamorelin has the most-established profile.
Can multiple metabolic peptides be combined in research?
Yes. The most-studied multi-mechanism stacks combine incretin agonists (Retatrutide), GHRH analogues (Tesamorelin), and cellular energy sensors (MOTS-c). Each targets distinct metabolic regulatory layers, and effects are typically additive rather than redundant.
What dose ranges are typical for metabolic peptides in research?
Retatrutide: 0.5-12 mg weekly subcutaneous. Tesamorelin: 2 mg daily subcutaneous. MOTS-c: 0.1-15 mg/kg per administration (animal). CJC-1295 + Ipamorelin: 100-300 microgram each, 1-3x daily. Specific protocols should reference the source research for the exact endpoint of interest.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. View source
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. View source
- Lee C, Zeng J, Drew BG, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. View source
Reviewed by
The Aeternum Labs Research Team
Compounds, COAs, and protocol design
Aeternum Labs verifies every batch in our library against published purity and identity standards. Category recommendations summarize publicly available scientific literature; final compound selection should reference the underlying primary research and your specific protocol requirements.
Research Disclaimer. All compounds discussed in this article are sold by Aeternum Labs for in vitro laboratory research purposes only. They are not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease or condition. Information presented is summarized from publicly available scientific literature and should not be construed as medical advice.